Clinical Oncology
Volume 19, Issue 2 , Pages 108-114 , March 2007

Ifosfamide Encephalopathy

  • T. Ajithkumar

      Affiliations

    • Department of Oncology, Addenbrooke's Oncology Centre, Hills Road, Cambridge CB2 2QQ, UK
    • Corresponding Author InformationAuthor for correspondence: T. Ajithkumar, 51 Eland Way, Cambridge CB1 9XQ, UK. Tel: +44-1223-413306.
    • ,
  • C. Parkinson

      Affiliations

    • Department of Oncology, Addenbrooke's Oncology Centre, Hills Road, Cambridge CB2 2QQ, UK
    • ,
  • F. Shamshad

      Affiliations

    • Department of Oncology, Essex County Hospital, Lexden Road, Colchester CO3 3NB, UK
    • ,
  • P. Murray

      Affiliations

    • Department of Oncology, Essex County Hospital, Lexden Road, Colchester CO3 3NB, UK

Received 5 August 2005 ,Revised 10 October 2006 ,Accepted 1 November 2006.

References 

  1. Kerbusch T, de Kraker J, Keizer HJ, et al. Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet. 2001;40:41–62
  2. Voute PA, van den Berg H, Behrendt H, Michiels E, de Kraker J. Ifosfamide in the treatment of pediatric malignancies. Semin Oncol. 1996;23:8–11
  3. Pratt CB. Ongoing clinical studies of ifosfamide for pediatric cancer in the United States. Semin Oncol. 1996;23:84–90
  4. Fleming RA. An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy. 1997;17:146S–154S
  5. Dechant KL, Brogden RN, Pilkington T, Faulds D. Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991;42:428–467
  6. Manegold C, Bischoff H, Fischer JR, et al. Oral ifosfamide–mesna: a clinical investigation in advanced non-small-cell lung cancer. Ann Oncol. 1992;3:723–726
  7. Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken JB. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82:291–294
  8. Merimsky O, Reider-Groswasser I, Wigler N, Chaitchik S. Encephalopathy in ifosfamide-treated patients. Acta Neurol Scand. 1992;86:521–525
  9. Kupfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50:249–252
  10. McVay JI, Wood AM. Suspected ifosfamide-induced neurotoxicity. Pharmacotherapy. 1999;19:1450–1455
  11. Chatton JY, Idle JR, Vagbo CB, Magistretti PJ. Insights into the mechanisms of ifosfamide encephalopathy: drug metabolites have agonistic effects on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/kainate receptors and induce cellular acidification in mouse cortical neurons. J Pharmacol Exp Ther. 2001;299:1161–1168
  12. Nicolao P, Giometto B. Neurological toxicity of ifosfamide. Oncology. 2003;65(Suppl 2):11–16
  13. Donegan S. Novel treatment for the management of ifosfamide neurotoxicity: rationale for the use of methylene blue. J Oncol Pharm Practice. 2001;6:153–165
  14. David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–280
  15. Primavera A, Audenino D, Cocito L. Ifosfamide encephalopathy and nonconvulsive status epilepticus. Can J Neurol Sci. 2002;29:180–183
  16. Meyer T, Ludolph AC, Munch C. Ifosfamide encephalopathy presenting with asterixis. J Neurol Sci. 2002;199:85–88
  17. Bruggers CS, Friedman HS, Tien R, Delong R. Cerebral atrophy in an infant following treatment with ifosfamide. Med Pediatr Oncol. 1994;23:380–383
  18. Pallotta MG, Velazco A, Sadler A. Ifosfamide extrapyramidal neurotoxicity. Cancer. 1992;70:2743–2745
  19. Anderson NR, Tandon DS. Ifosfamide extrapyramidal neurotoxicity. Cancer. 1991;68:72–75
  20. Wengs WJ, Talwar D, Bernard J. Ifosfamide-induced nonconvulsive status epilepticus. Arch Neurol. 1993;50:1104–1105
  21. Cantwell BM, Carmichael J, Ghani S, Harris AL. A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. Cancer Chemother Pharmacol. 1988;21:49–52
  22. Frisk P, Stalberg E, Stromberg B, Jakobson A. Painful peripheral neuropathy after treatment with high-dose ifosfamide. Med Pediatr Oncol. 2001;37:379–382
  23. Shuper A, Stein J, Goshen J, Kornreich L, Yaniv I, Cohen IJ. Subacute central nervous system degeneration in a child: an unusual manifestation of ifosfamide intoxication. J Child Neurol. 2000;15:481–483
  24. Meanwell CA, Blake AE, Kelly KA, Honigsberger L, Blackledge G. Prediction of ifosfamide/mesna associated encephalopathy. Eur J Cancer Clin Oncol. 1986;22:815–819
  25. Rieger C, Fiegl M, Tischer J, Ostermann H, Schiel X. Incidence and severity of ifosfamide-induced encephalopathy. Anticancer Drugs. 2004;15:347–350
  26. Matsumine AKI, Ieguchi M, Hirosima K, Aoki Y, Araki N. Ifosfamide (IFM)-induced encephalopathy in bone and soft tissue sarcoma patients. Proc Am Soc Clin Oncol. 2001;20:1454;[abstract]
  27. Watkin SW, Husband DJ, Green JA, Warenius HM. Ifosfamide encephalopathy: a reappraisal. Eur J Cancer Clin Oncol. 1989;25:1303–1310
  28. Zulian GB, Tullen E, Maton B. Methylene blue for ifosfamide-associated encephalopathy. N Engl J Med. 1995;332:1239–1240
  29. Pratt CB, Green AA, Horowitz ME, et al. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol. 1986;4:1253–1261
  30. Gieron MA, Barak LS, Estrada J. Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors. J Neurooncol. 1988;6:29–30
  31. Pratt CB, Goren MP, Meyer WH, Singh B, Dodge RK. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol. 1990;8:1399–1401
  32. Curtin JP, Koonings PP, Gutierrez M, Schlaerth JB, Morrow CP. Ifosfamide-induced neurotoxicity. Gynecol Oncol. 1991;42:193–196191–192
  33. Goren MP, Wright RK, Pratt CB, et al. Potentiation of ifosfamide neurotoxicity, hematotoxicity, and tubular nephrotoxicity by prior cis-diamminedichloroplatinum(II) therapy. Cancer Res. 1987;47:1457–1460
  34. Danesh MM, De Giorgio CM, Beydoun SR, Kemp RA. Ifosfamide encephalopathy. J Toxicol Clin Toxicol. 1989;27:293–298
  35. Cantwell BM, Idle M, Millward MJ, Hall G, Lind MJ. Encephalopathy with hyponatremia and inappropriate arginine vasopressin secretion following an intravenous ifosfamide infusion. Ann Oncol. 1990;1:232
  36. Ghosn M, Carde P, Leclerq B, et al. Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. Bull Cancer. 1988;75:391–392
  37. Chang TK, Yu L, Maurel P, Waxman DJ. Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 1997;57:1946–1954
  38. Morgan DB, Young RM. Acute transient hypokalaemia: new interpretation of a common event. Lancet. 1982;2:751–752
  39. Kirch C, Gachot B, Germann N, Blot F, Nitenberg G. Recurrent ifosfamide-induced hyponatraemia. Eur J Cancer. 1997;33:2438–2439
  40. Culine S, Ghosn M, Droz JP. Inappropriate antidiuretic hormone secretion induced by ifosfamide. Eur J Cancer. 1990;26:922
  41. Gonzalez-Angulo AM, Orzano JA, Davila E. Ifosfamide-induced encephalopathy. South Med J. 2002;95:1215–1217
  42. Cantwell BM, Harris AL. Ifosfamide/mesa and encephalopathy. Lancet. 1985;1:752
  43. Cerny T, Kupfer A. The enigma of ifosfamide encephalopathy. Ann Oncol. 1992;3:679–681
  44. Meanwell CA, Kelly KA, Blackledge G. Avoiding ifosfamide/mesna encephalopathy. Lancet. 1986;2:406
  45. Perren TJ, Turner RC, Smith IE. Encephalopathy with rapid infusion ifosfamide/mesna. Lancet. 1987;1:390–391
  46. McCallum AK. Ifosfamide/mesna encephalopathy. Lancet. 1987;1:987
  47. Kupfer A, Aeschlimann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet. 1994;343:763–764
  48. Ferrero JM, Eftekari P, Largillier R, Dreyfus G, Namer M. Treatment of ifosfamide induced encephalopathy with methylene-blue. Bull Cancer. 1995;82:598–599
  49. Demandt M, Wandt H. Successful treatment with methylene blue of ifosfamide-induced central nervous system effects. Dtsch Med Wochenschr. 1996;121:575
  50. Alonso JL, Nieto Y, Lopez JA, Martin M, Diaz-Rubio E. Ifosfamide encephalopathy and methylene-blue: a case report. Ann Oncol. 1996;7:643–644
  51. Dourthe LM, Coutant G, Desrame J, Merrer J, Daly JP. Ifosfamide-related encephalopathy. Report of two cases. Rev Med Interne. 1999;20:264–266
  52. Turner AR, Duong CD, Good DJ. Methylene blue for the treatment and prophylaxis of ifosfamide-induced encephalopathy. Clin Oncol (R Coll Radiol). 2003;15:435–439
  53. Kasper B, Harter C, Meissner J, et al. Prophylactic treatment of known ifosfamide-induced encephalopathy for chemotherapy with high-dose ifosfamide?. Support Care Cancer. 2004;12:205–207
  54. Raj AB, Bertolone SJ, Jaffe N. Methylene blue reversal of ifosfamide-related encephalopathy. J Pediatr Hematol Oncol. 2004;26:116
  55. Aeschlimann C, Cerny T, Kupfer A. Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos. 1996;24:1336–1339
  56. Harpey JP, Charpentier C, Coude M. Methylene-blue for riboflavin-unresponsive glutaricaciduria type II. Lancet. 1986;1:391
  57. DiMaggio JR, Brown R, Baile WF, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer. 1994;73:1509–1514
  58. Carlson L, Goren MP, Bush DA, et al. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemother Pharmacol. 1998;41:140–146
  59. Antman KH, Elias A, Ryan L. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol. 1990;17:68–73
  60. Keizer HJ, Ouwerkerk J, Welvaart K, van der Velde CJ, Cleton FJ. Ifosfamide treatment as a 10-day continuous intravenous infusion. J Cancer Res Clin Oncol. 1995;121:297–302
  61. Simonian NA, Gilliam FG, Chiappa KH. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology. 1993;43:2700–2702
  62. Buesa JM, Garcia-Teijido P, Losa R, Fra J. Treatment of ifosfamide encephalopathy with intravenous thiamin. Clin Cancer Res. 2003;9:4636–4637
  63. Koschuth A, Spath-Schwalbe PE, Possinger K. Methylene blue in ifosfamide-induced encephalopathy. Dtsch Med Wochenschr. 1996;121:1210

PII: S0936-6555(06)00417-1

doi: 10.1016/j.clon.2006.11.003

Clinical Oncology
Volume 19, Issue 2 , Pages 108-114 , March 2007

Article Tools

* Image Usage & Resolution